Gemini Therapeutics (GMTX) Issues Corporate Update Feb 28, 2022 08:32AM
Gemini Therapeutics Provides Corporate Update Feb 28, 2022 08:30AM
Gemini Therapeutics (GMTX) Issues GEM103 Program Update Jan 10, 2022 08:06AM
Gemini Therapeutics Provides GEM103 Program Update Jan 10, 2022 08:00AM
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 15, 2021 07:00AM


Nov 12, 2021 08:30AM Gemini Therapeutics Announces Poster Presentation at AAO 2021
Nov 11, 2021 07:00AM Gemini Therapeutics to Participate in Upcoming Investor Conferences
Oct 19, 2021 07:00AM Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
Oct 5, 2021 07:00AM Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
Sep 10, 2021 08:30AM Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
Sep 9, 2021 07:00AM Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
Sep 7, 2021 07:00AM Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 30, 2021 07:00AM Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
Aug 12, 2021 07:00AM Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Jun 22, 2021 04:06PM Gemini Therapeutics (GMTX) Announces Positive Initial Data From Ongoing Phase 2a Study of GEM103
Jun 22, 2021 04:05PM Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration